Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

New Culture Technique Will Promote the Study of Leukemic Stem Cells

By BiotechDaily International staff writers
Posted on 02 Apr 2014
Image: Acute myeloid leukemia cells presenting anomalies in standard growth conditions (top). Acute myeloid leukemia cells preserving their leukemic cell features following in vitro culture with the two chemical molecules referred to in the study (below) (Photo courtesy of the Université de Montréal).
Image: Acute myeloid leukemia cells presenting anomalies in standard growth conditions (top). Acute myeloid leukemia cells preserving their leukemic cell features following in vitro culture with the two chemical molecules referred to in the study (below) (Photo courtesy of the Université de Montréal).
A multidisciplinary team of cancer researchers has developed a method for maintaining leukemic stem cells (LSCs) in culture, which will aid in the study of this class of cancer cells and the development of new drugs.

It has proven difficult to study LSCs, as currently available culture conditions do not prevent their spontaneous differentiation into full-blown acute myeloid leukemia (AML) cells. To overcome these constraints the “Leucégène” research group of investigators at the Université de Montréal (Canada) conducted a high-throughput chemical screen to identify small molecules that could inhibit differentiation and support LSC activity in vitro.

They reported in the February 23, 2014, online edition of the journal Nature Methods that they were able to identify two chemical compounds that, when added to the culture medium, could maintain functional human LSCs alive for at least seven days in vitro. One of the compounds suppressed the aryl-hydrocarbon receptor (AhR) pathway, which is inactive in vivo but rapidly activated ex vivo in AML cells. The other compound, UM729, collaborated with AhR suppressors in preventing AML cell differentiation.

These findings provide newly defined culture conditions for improved ex vivo culture of human LSCs and primary AML cells. “This research breakthrough demonstrates the advantage of working in a multidisciplinary team like the “Leucégène” research group,” said senior author Dr. Guy Sauvageau, professor of medicine at the Université de Montréal. “Access to cells of leukemia patients and to IRIC’s [The Institute for Research in Immunology and Cancer of the Université de Montréal] state-of-the-art facilities are also key factors in pursuing ground-breaking research.”

Related Links:

Université de Montréal



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.